Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2020 August;111(4) > Minerva Medica 2020 August;111(4):362-4

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

SPECIAL ARTICLE   

Minerva Medica 2020 August;111(4):362-4

DOI: 10.23736/S0026-4806.20.06616-1

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Hyper-immune/convalescent plasma: an old option and a valid strategy for treatment of COVID-19?

Daniele SAVERINO 1, 2

1 Department of Experimental Medicine, University of Genoa, Genoa, Italy; 2 San Martino Hospital, Genoa, Italy



Currently, there are no approved specific antiviral agents for novel coronavirus disease (COVID-19). Hyper-immune/convalescent plasma derived from recently recovered donors seems to be useful to treat COVID-19 patients, an addition to maximal supportive care and antiviral agents. The endpoints are the improvement of clinical symptoms and laboratory parameters of these patients. However, the efficacy of hyper-immune/convalescent plasma treatment for severe infectious diseases is still controversial. The optimal dose and time point, as well as the clinical benefit of hyper-immune/convalescent plasma therapy, needs further investigation in larger well-controlled trials.


KEY WORDS: COVID-19 serotherapy; COVID-19; Therapeutics

top of page